carvacrol has been researched along with Cirrhoses, Experimental Liver in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hashemnia, M; Karimi, J; Khodadadi, I; Mohseni, R; Tavilani, H | 1 |
Al-Assaf, AH; Aristatile, B; Pugalendi, KV | 1 |
2 other study(ies) available for carvacrol and Cirrhoses, Experimental Liver
Article | Year |
---|---|
Carvacrol ameliorates the progression of liver fibrosis through targeting of Hippo and TGF-β signaling pathways in carbon tetrachloride (CCl
Topics: Acyltransferases; Animals; Anti-Inflammatory Agents; Apoptosis Regulatory Proteins; Carbon Tetrachloride; Cymenes; Disease Progression; Liver; Liver Cirrhosis, Experimental; Male; Monoterpenes; Rats, Wistar; Signal Transduction; Transcription Factors; Transforming Growth Factor beta; YAP-Signaling Proteins | 2019 |
Carvacrol suppresses the expression of inflammatory marker genes in D-galactosamine-hepatotoxic rats.
Topics: Animals; Blotting, Western; Cyclooxygenase 2; Cymenes; Galactosamine; Interleukin-6; Liver Cirrhosis, Experimental; Male; Monoterpenes; NF-kappa B; Nitric Oxide Synthase Type II; Protective Agents; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Silymarin; Tumor Necrosis Factor-alpha | 2013 |